MyMSTeam

CAR-T cell therapy is a bit different from the stem cell transplant trials (AHSCT) that have been most studied in MS, but it's great that you're exploring cutting-edge options! The most researched stem cell approach for MS is autologous hematopoietic stem cell transplantation (AHSCT), which uses a person's own stem cells to Show Full Answer

CAR-T cell therapy is a bit different from the stem cell transplant trials (AHSCT) that have been most studied in MS, but it's great that you're exploring cutting-edge options! The most researched stem cell approach for MS is autologous hematopoietic stem cell transplantation (AHSCT), which uses a person's own stem cells to essentially "reset" the immune system.

Here's what the research on AHSCT has shown so far:

- In one UK study of 271 people with MS, 94% had no relapses after two years
- After four years, 89% remained relapse-free
- Nearly 92% showed no worsening disability after two years
- A Canadian study found relapse rates dropped to zero after transplantation However, the risks are real and worth knowing about:

- The procedure requires chemotherapy to destroy the existing immune system first
- There is a small but serious risk of mortality
- Immune suppression can lead to serious infections

AHSCT is not yet FDA-approved for MS and is generally only recommended for aggressive MS cases. Participating in a clinical trial may be one way to access this therapy safely.

Talking to a neurologist or MS specialist about whether any current trials might be a good fit is always a smart first step!

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Study: Nearly 90% Are Relapse-Free 2 Years After Stem Cell Transplant for MS

MS Relapse Rates Drop to Zero Following Stem Cell Transplants — But ‘Risks Are Real,’ Study Says